80.60
+2.52%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Lyka Labs
Its shares trade on NSE under the ticker LYKALABS.NS. It has been listed since 9 February 1995. In the fiscal year to 31 March 2026, it reported revenue of ₹1.28bn and a net loss of ₹100.3m. At that date it held total assets of ₹1.75bn and shareholders' equity of ₹923.9m.
Lyka Labs Ltd. is a holding company, which engages in the manufacture of pharmaceutical formulations and active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra. The firm is focused on lyophilization - formulations/bulk sterile active pharmaceutical ingredients (APIs), and new product development including novel drug delivery systems in both topical preparation and lyophilized products. The firm manufactures pharmaceutical products, such as dry powder, liquid injections, lyophilized injections, ointment/creams and lotions, and external preparations for several international markets and the domestic market. The company offers formulations, such as emollient, anti-aging, cleansing lotion, hair care products, anti-dandruff shampoo, sunscreen, anti-acne, antioxidant tablets, antioxidants combination, proton pump inhibitor, anti-fungal, anti-malarial, anti-bacterial, corticosteroid hormones and cephalosporins. The firm's subsidiaries include Lyka BDR International Limited and Lyka Exports Limited.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 Feb 1995
- Website
- lykalabs.com ↗
Leadership
Pay as last reported
- Mr. Kunal GandhiChief Executive Officer, Managing Director
- Mr. Yogesh ShahChief Financial Officer, Additional Executive Director, since 2014
- Mr. Shekhar SinghCompany Secretary and Compliance Officer
- Mr. Prashant GodhaAdditional Director
- Mr. Shashil MendonsaAdditional Director
- Shri. Vinod ShanbhagAdditional Independent Director
- Mr. Neeraj GolasAdditional Non-Executive Independent Director
- Ms. Dhara ShahAdditional Non-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Lyka Labs Ltd manufactures pharmaceutical formulations and active pharmaceutical ingredients in Mumbai, Maharashtra.
- The company focuses on lyophilization for sterile APIs and novel drug delivery systems in topical preparations.
- Lyka Labs Ltd offers a wide range of products including anti-dandruff shampoo, proton pump inhibitors, and anti-malarial formulations.
Weaknesses
- Lyka Labs Ltd has a single IPO date of February 9, 1995, indicating limited recent market activity.
- The company's operations are confined to Mumbai, Maharashtra, restricting geographic expansion.
- Lyka Labs Ltd's subsidiaries include Lyka BDR International Limited and Lyka Exports Limited, which may limit diversification.
Opportunities
- Lyka Labs Ltd can expand its lyophilized product line for international markets beyond current offerings.
- The firm's focus on novel drug delivery systems presents opportunities for new product development in topical preparations.
- Lyka Labs Ltd can leverage its existing formulations like anti-acne and antioxidant tablets to enter new market segments.
Threats
- Lyka Labs Ltd faces competition from other pharmaceutical manufacturers in the Mumbai, Maharashtra region.
- The company's reliance on a single IPO date of February 9, 1995, may indicate outdated market strategies.
- Lyka Labs Ltd's product range, including anti-fungal and anti-bacterial formulations, could face regulatory challenges in international markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.